FTO Downregulation Linked to Poor Prognosis in Liver Cancer

Strategic Insights -

Researchers at Fudan University have shed light on the molecular mechanisms behind liver cancer progression, with a focus on the role of N6-methyladenosine (m6A) modifications and the demethylase FTO. The study analyzed m6A expression in a cohort of 323 HCC patients and found that high m6A levels were correlated with poorer overall survival and recurrence-free survival rates.

Key Takeaways:

  • Elevated m6A levels in HCC tissues were found in 57.3% of patients, with a significant correlation with poorer overall survival and recurrence-free survival rates.
  • FTO, a demethylase, was significantly downregulated in HCC tissues and cell lines, particularly in highly metastatic lines.
  • Overexpression of FTO in HCC cells reduced proliferation, migration, and invasion, whereas FTO knockdown had the opposite effect.
  • In vivo, FTO overexpression decreased tumor growth and metastasis.
  • The study identified VEGFA as a key gene downregulated by FTO, implicating its role in angiogenesis and tumor progression.
  • The researchers concluded that FTO acts as a tumor suppressor by negatively regulating VEGFA expression.
  • This study highlights the significance of m6A modifications in HCC and provides a foundation for future research on targeted therapies.

Statistics:

  • 57.3% of HCC patients showed increased m6A expression.
  • High m6A levels were correlated with poorer overall survival (OS) and recurrence-free survival (RFS) rates.
  • FTO was significantly downregulated in HCC tissues and cell lines, particularly in highly metastatic lines (58.5% of highly metastatic lines showed FTO downregulation).
  • Overexpression of FTO reduced tumor growth by 23.1% and metastasis by 18.8% in vivo.

Sources:

  • Zhang, Y., et al. (2025). FTO downregulation-mediated m6A modification resulting in enhanced hepatocellular carcinoma invasion. Cell & Bioscience, 15(1), 1-15.
  • Chen, Q., et al. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University.